BNT-312 is under clinical development by BioNTech and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BNT-312’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GEN-1042 is under development for the treatment of solid tumors including relapsed or refractory non-small cell lung cancer, colorectal cancer, pacreatic cancer, head and neck cancer, peritoneal cancer, gastric cancer, ovarian cancer, fallopian cancer, Uterine cancer, and endometrial cancer . The therapeutic candidate is a bi-specific monoclonal antibody being developed based on BioNTech’s immunomodulatory and DuoBody technology. It targets CD40 and 4-1BB tumor specific antigen.
BioNTech is a biotechnology company that develops immunotherapies for cancer and infectious diseases. It is investigating mRNA therapeutics, engineered cell and gene therapies, antibodies and small molecule immunomodulators to treat advanced melanoma, solid tumors, non-small cell lung cancer (NSCLC), prostate, head and neck, ovarian, pancreatic and triple negative breast cancer. The company is also evaluating treatments for HIV, tuberculosis, malaria, hepatitis B, influenza, and COVID-19. BioNTech uses FixVac and iNeST technology platforms to discover and develop cancer immunotherapies targeting antigens and neoantigens. It works in partnership with Genentech Inc, Pfizer, Genmab AS and other biopharmaceutical companies to develop its pipeline products. BioNTech is headquartered in Mainz, Rhineland-Palatinate, Germany.
For a complete picture of BNT-312’s drug-specific PTSR and LoA scores, buy the report here.